Fibroblast growth factor receptor 3-mediated reactivation of ERK signaling promotes head and neck squamous cancer cell insensitivity to MEK inhibition

Myung Jin Ban, Hyung Kwon Byeon, Yeon Ju Yang, Sojung An, Jae Wook Kim, Ji Hoon Kim, Da Hee Kim, Jaemoon Yang, Hyunjung Kee, Yoonwoo Koh

Research output: Contribution to journalArticle

Abstract

Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) has been a longstanding challenge for head and neck oncologists, and current treatments still have limited efficacy. ERK is aberrantly overexpressed and activated in HNSCC. Herein, we aimed to investigate the cause of the limited therapeutic effect of selumetinib, a selective inhibitor of MEK in HNSCC, as MEK/ERK reactivation inevitably occurs. We assessed the effects of combining selumetinib with fibroblast growth factor receptor 3 (FGFR3) inhibitor (PD173074) on tumor growth. Selumetinib transiently inhibited MAPK signaling and reactivated ERK signaling in HNSCC cells. Rebound in the ERK and Akt pathways in HNSCC cells was accompanied by increased FGFR3 signaling after selumetinib treatment. Feedback activation of FGFR3 was a result of autocrine secretion of the FGF2 ligand. The FGFR3 inhibitor PD173074 prevented MAPK rebound and sensitized the response of HNSCC cells to selumetinib. These results provided rational therapeutic strategies for clinical studies of this subtype of patients that show a poor prognosis with selumetinib. Our data provide a rationale for combining a MEK inhibitor with inhibitors of feedback activation of FGFR3 signaling in HNSCC cells. ERK rebound as a result of the upregulation of FGFR3 and the ligand FGF2 diminished the antitumor effects of selumetinib, which was overcome by combination treatment with the FGFR3 inhibitor.

Original languageEnglish
Pages (from-to)3816-3825
Number of pages10
JournalCancer Science
Volume109
Issue number12
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

Receptor, Fibroblast Growth Factor, Type 3
Mitogen-Activated Protein Kinase Kinases
Head and Neck Neoplasms
Epithelial Cells
Fibroblast Growth Factor 2
Ligands
MAP Kinase Signaling System
Therapeutic Uses
Therapeutics
Carcinoma, squamous cell of head and neck
AZD 6244
Neck
Up-Regulation
Head

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Ban, Myung Jin ; Byeon, Hyung Kwon ; Yang, Yeon Ju ; An, Sojung ; Kim, Jae Wook ; Kim, Ji Hoon ; Kim, Da Hee ; Yang, Jaemoon ; Kee, Hyunjung ; Koh, Yoonwoo. / Fibroblast growth factor receptor 3-mediated reactivation of ERK signaling promotes head and neck squamous cancer cell insensitivity to MEK inhibition. In: Cancer Science. 2018 ; Vol. 109, No. 12. pp. 3816-3825.
@article{5736fc9ef46a4aff9b617109de62db33,
title = "Fibroblast growth factor receptor 3-mediated reactivation of ERK signaling promotes head and neck squamous cancer cell insensitivity to MEK inhibition",
abstract = "Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) has been a longstanding challenge for head and neck oncologists, and current treatments still have limited efficacy. ERK is aberrantly overexpressed and activated in HNSCC. Herein, we aimed to investigate the cause of the limited therapeutic effect of selumetinib, a selective inhibitor of MEK in HNSCC, as MEK/ERK reactivation inevitably occurs. We assessed the effects of combining selumetinib with fibroblast growth factor receptor 3 (FGFR3) inhibitor (PD173074) on tumor growth. Selumetinib transiently inhibited MAPK signaling and reactivated ERK signaling in HNSCC cells. Rebound in the ERK and Akt pathways in HNSCC cells was accompanied by increased FGFR3 signaling after selumetinib treatment. Feedback activation of FGFR3 was a result of autocrine secretion of the FGF2 ligand. The FGFR3 inhibitor PD173074 prevented MAPK rebound and sensitized the response of HNSCC cells to selumetinib. These results provided rational therapeutic strategies for clinical studies of this subtype of patients that show a poor prognosis with selumetinib. Our data provide a rationale for combining a MEK inhibitor with inhibitors of feedback activation of FGFR3 signaling in HNSCC cells. ERK rebound as a result of the upregulation of FGFR3 and the ligand FGF2 diminished the antitumor effects of selumetinib, which was overcome by combination treatment with the FGFR3 inhibitor.",
author = "Ban, {Myung Jin} and Byeon, {Hyung Kwon} and Yang, {Yeon Ju} and Sojung An and Kim, {Jae Wook} and Kim, {Ji Hoon} and Kim, {Da Hee} and Jaemoon Yang and Hyunjung Kee and Yoonwoo Koh",
year = "2018",
month = "12",
day = "1",
doi = "10.1111/cas.13839",
language = "English",
volume = "109",
pages = "3816--3825",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "12",

}

Fibroblast growth factor receptor 3-mediated reactivation of ERK signaling promotes head and neck squamous cancer cell insensitivity to MEK inhibition. / Ban, Myung Jin; Byeon, Hyung Kwon; Yang, Yeon Ju; An, Sojung; Kim, Jae Wook; Kim, Ji Hoon; Kim, Da Hee; Yang, Jaemoon; Kee, Hyunjung; Koh, Yoonwoo.

In: Cancer Science, Vol. 109, No. 12, 01.12.2018, p. 3816-3825.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Fibroblast growth factor receptor 3-mediated reactivation of ERK signaling promotes head and neck squamous cancer cell insensitivity to MEK inhibition

AU - Ban, Myung Jin

AU - Byeon, Hyung Kwon

AU - Yang, Yeon Ju

AU - An, Sojung

AU - Kim, Jae Wook

AU - Kim, Ji Hoon

AU - Kim, Da Hee

AU - Yang, Jaemoon

AU - Kee, Hyunjung

AU - Koh, Yoonwoo

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) has been a longstanding challenge for head and neck oncologists, and current treatments still have limited efficacy. ERK is aberrantly overexpressed and activated in HNSCC. Herein, we aimed to investigate the cause of the limited therapeutic effect of selumetinib, a selective inhibitor of MEK in HNSCC, as MEK/ERK reactivation inevitably occurs. We assessed the effects of combining selumetinib with fibroblast growth factor receptor 3 (FGFR3) inhibitor (PD173074) on tumor growth. Selumetinib transiently inhibited MAPK signaling and reactivated ERK signaling in HNSCC cells. Rebound in the ERK and Akt pathways in HNSCC cells was accompanied by increased FGFR3 signaling after selumetinib treatment. Feedback activation of FGFR3 was a result of autocrine secretion of the FGF2 ligand. The FGFR3 inhibitor PD173074 prevented MAPK rebound and sensitized the response of HNSCC cells to selumetinib. These results provided rational therapeutic strategies for clinical studies of this subtype of patients that show a poor prognosis with selumetinib. Our data provide a rationale for combining a MEK inhibitor with inhibitors of feedback activation of FGFR3 signaling in HNSCC cells. ERK rebound as a result of the upregulation of FGFR3 and the ligand FGF2 diminished the antitumor effects of selumetinib, which was overcome by combination treatment with the FGFR3 inhibitor.

AB - Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) has been a longstanding challenge for head and neck oncologists, and current treatments still have limited efficacy. ERK is aberrantly overexpressed and activated in HNSCC. Herein, we aimed to investigate the cause of the limited therapeutic effect of selumetinib, a selective inhibitor of MEK in HNSCC, as MEK/ERK reactivation inevitably occurs. We assessed the effects of combining selumetinib with fibroblast growth factor receptor 3 (FGFR3) inhibitor (PD173074) on tumor growth. Selumetinib transiently inhibited MAPK signaling and reactivated ERK signaling in HNSCC cells. Rebound in the ERK and Akt pathways in HNSCC cells was accompanied by increased FGFR3 signaling after selumetinib treatment. Feedback activation of FGFR3 was a result of autocrine secretion of the FGF2 ligand. The FGFR3 inhibitor PD173074 prevented MAPK rebound and sensitized the response of HNSCC cells to selumetinib. These results provided rational therapeutic strategies for clinical studies of this subtype of patients that show a poor prognosis with selumetinib. Our data provide a rationale for combining a MEK inhibitor with inhibitors of feedback activation of FGFR3 signaling in HNSCC cells. ERK rebound as a result of the upregulation of FGFR3 and the ligand FGF2 diminished the antitumor effects of selumetinib, which was overcome by combination treatment with the FGFR3 inhibitor.

UR - http://www.scopus.com/inward/record.url?scp=85056637883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056637883&partnerID=8YFLogxK

U2 - 10.1111/cas.13839

DO - 10.1111/cas.13839

M3 - Article

VL - 109

SP - 3816

EP - 3825

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 12

ER -